Floatz logo

Umbralisib

Recurrent Nodal Marginal Zone Lymphoma

Yazeed SawalhaSmall moleculePhase 1Active
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
19/ 100
Competitive Position
89/ 100

Competitive context

37 Active assets in the Recurrent Nodal Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
ETOPOSIDE
University of California, Davis
Phase 2BB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BB

View all 50 →

Same molecule, other indications

Umbralisib is also rated in:

marginal zone lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
follicular lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →